Tranexam, 250 mg 10 pcs

Tranexamic has a hemostatic, anti-inflammatory, anti-allergic effect.

Tranexamic acid is an antifibrinolytic agent specifically inhibiting the activation of profibrinolysin (plasminogen) and its conversion into fibrinolysin (plasmin).

It has local and systemic hemostatic action in bleeding associated with increased fibrinolysis as well as anti-inflammatory, anti-allergic, anti-infective and

anti-tumor action due to suppression of formation of kinins and other active peptides involved in allergic and inflammatory reactions.

The intrinsic analgesic activity of tranexamic acid was confirmed in the experiment, as well as the supersumptive andotensive effect with respect to the analgesic activity of opiates.

Pharmacokinetics

The distribution in tissues is relatively uniform (exception is cerebrospinal fluid, where the concentration is 1/10 of the plasma concentration); penetrates through the placental and blood-brain barrier, into breast milk (about 1% of the concentration in maternal plasma).

Detected in seminal fluid, where it reduces fibrinolytic activity, but does not affect sperm migration.

The initial volume of distribution is 9-12 liters. Binding with plasma proteins (profibrinolysin) is less than 3%. In the blood about 3% is bound to protein (plasminogen).

The concentration in cerebrospinal fluid is 1/10 of plasma. Total renal clearance is equal to plasma clearance. Antifibrinolytic concentration in various tissues persists for 17 hours, in plasma – up to 7-8 hours.

A small part is metabolized. The concentration-time curve has a three-phase shape with a half-life of -2 hours in the terminal phase. Total renal clearance is equal to plasma clearance (7 l/h).

Extracted by the kidneys (main route – glomerular filtration) – more than 95% unchanged in the first 12 hours.

Two metabolites of tranexamic acid have been identified: N-acetylated and deaminated derivatives. There is a risk of cumulation of tranexamic acid in impaired renal function.

Indications

Bleeding or risk of bleeding due to increased fibrinolysis, both generalized (bleeding during surgery and in the postoperative period, postnatal bleeding, manual removal of afterbirth,

chorion detachment, bleeding during pregnancy, malignant neoplasms of the pancreas and prostate, hemophilia, hemorrhagic complications of fibrinolytic therapy,

thrombocytopenic purpura, leukemia, liver disease, prior therapy with streptokinase), and local (uterine, nasal, pulmonary, gastrointestinal bleeding, hematuria,

Active ingredient

Composition

How to take, the dosage

Ingestion, regardless of meals.

Short-term treatment of bleeding due to increased fibrinolysis: The recommended standard dose of tranexamic acid is 15-25 mg/kg body weight, an average of 1000-1500 mg 2-3 times daily.

Application of the drug in special groups of patients

Kidney function disorders

In patients with mild to moderate impaired renal excretory function, adjustment of the dose and frequency of tranexamic acid is necessary:

Interaction

In concomitant use with hemostatic drugs and hemocoagulase, activation of thrombosis is possible.

The solution should not be added to blood products and solutions containing penicillin.

Special Instructions

Synopsis

Contraindications

Side effects

Pregnancy use

Similarities